CJC-1295 without DAC: Evidence-Based Review: Clinical Data and Practical Applications

Medically reviewed by Dr. Sarah Chen, PharmD, BCPS

An in-depth evidence-based review on CJC-1295 without DAC, examining clinical data, pharmacology, therapeutic potential, and practical applications in peptide therapy.

Introduction to CJC-1295 Without DAC

CJC-1295 is a synthetic peptide analog of growth hormone-releasing hormone (GHRH) designed to stimulate endogenous growth hormone (GH) secretion. Among its formulations, CJC-1295 without Drug Affinity Complex (DAC) stands out due to its distinct pharmacokinetics and clinical applications. This article provides an evidence-based, comprehensive review of CJC-1295 without DAC, focusing on clinical data, safety profile, and practical therapeutic uses.

The distinction between CJC-1295 with DAC and without DAC lies primarily in their half-lives and binding affinities to serum albumin; without DAC, the peptide has a much shorter half-life, impacting dosing intervals and physiological effects. Understanding these differences is vital for clinicians and researchers employing peptide therapies aiming to harness the anabolic and metabolic benefits of GH stimulation.

Pharmacological Profile and Mechanism of Action

CJC-1295 without DAC is a 29-amino-acid synthetic analog of GHRH, mimicking endogenous GHRH's ability to bind and activate GHRH receptors on pituitary somatotrophs, stimulating pulsatile GH release. Unlike the DAC-modified version, which has a prolonged half-life (~8 days), the non-DAC variant exhibits a short half-life, around 30 minutes to 1 hour, necessitating more frequent administration to maintain elevated GH levels.

The peptide's action differs significantly from direct GH administration; it induces endogenous, physiologic pulsatile release rather than supraphysiologic steady-state GH concentrations. This pulsatility is thought to more closely replicate natural GH dynamics, potentially reducing side effects while promoting beneficial anabolic and lipolytic effects.

Pharmacokinetics Summary

| Parameter | CJC-1295 with DAC | CJC-1295 without DAC |

|----------------------|---------------------------|---------------------------|

| Half-life | ~7-8 days | ~30 minutes to 1 hour |

| Administration | 1-2 times/week | Daily or multiple times/day|

| GH Secretion Profile | Prolonged, sustained | Pulsatile, short bursts |

| Albumin Binding | Strong (via DAC) | Minimal |

Clinical Data and Evidence

Human Studies

Clinical studies evaluating CJC-1295 without DAC primarily explore its ability to increase GH and consequently IGF-1 levels, as well as monitor safety and tolerability. A seminal early-phase study by Teichman et al. (2006) demonstrated that CJC-1295 without DAC, when administered intravenously, produced rapid, dose-dependent increases in GH and IGF-1 levels in healthy subjects with a return to baseline within 24 hours [1].

Another investigation by Bowers et al. (2008) evaluated subcutaneous administration and found similar short-lived rises in GH, confirming the need for multiple daily doses to maintain elevated anabolic hormone levels [2]. These studies collectively established proof of concept that CJC-1295 without DAC acts as a potent stimulator of the somatotropic axis.

Safety Profile

The safety data from early clinical trials and subsequent off-label and research use indicate CJC-1295 without DAC is generally well tolerated. Reported adverse effects are mild and typically include injection site reactions, transient flushing, and occasional headaches. Unlike continuous GH therapy or CJC-1295 with DAC, shorter half-life formulations are less likely to cause sustained elevations leading to insulin resistance or edema.

While long-term safety data remain limited, current evidence suggests a favorable risk-benefit profile when administered under medical supervision.

Comparative Efficacy

One controlled human study compared CJC-1295 without DAC and the DAC-modified version, finding that while both peptides increase IGF-1, the DAC variant maintains elevated IGF-1 levels for significantly longer, reducing injection frequency [3]. However, the non-DAC form’s pulsatile release pattern may align better with physiological GH secretion and could minimize some risks associated with prolonged elevated GH.

Practical Applications in Clinical and Research Settings

Indications and Uses

CJC-1295 without DAC has been explored for multiple indications, including:

  • GH Deficiency (GHD): As an alternative or adjunct to recombinant human GH (rhGH), stimulating endogenous secretion.
  • Anti-Aging Therapy: Through increased IGF-1 production, potentially improving muscle mass, bone density, and skin elasticity.
  • Metabolic Syndrome and Obesity: Enhancing lipolysis and improving body composition.
  • Athletic Performance: Augmenting recovery and muscle growth, though this use remains controversial and off-label.

    • Dosage and Administration

    Given its short half-life, typical dosing regimens involve daily subcutaneous injections, often administered 1-3 times per day to simulate natural GH pulsatility. Dosages vary widely based on treatment goals, patient factors, and formulation purity, generally ranging between 100 to 200 mcg per injection.

    Combination Therapies

    Combining CJC-1295 without DAC with other peptides such as Ipamorelin, a ghrelin receptor agonist, has demonstrated synergistic effects on GH release, amplifying therapeutic outcomes without increasing adverse events [4]. These combinations harness complementary pathways in the GH axis.

    Monitoring and Follow-Up

    Clinical use mandates regular monitoring of IGF-1 levels, glucose metabolism, and potential side effects. Adjustments to dosing are made based on therapeutic response and hormonal assays.

    Comparative Summary Table

    | Feature | CJC-1295 with DAC | CJC-1295 without DAC |

    |----------------------------|-------------------------------------------------------|--------------------------------------------------|

    | Half-life | Long (~7-8 days) | Short (~30 min to 1 hour) |

    | Dosing Frequency | 1-2 times per week | Daily or multiple times daily |

    | Mode of GH release | Sustained, prolonged | Physiological, pulsatile |

    | Side Effects | Risk of prolonged IGF-1 elevation, edema, insulin resistance | Generally milder, injection site reactions |

    | Preferred Clinical Use | Convenience, chronic conditions requiring steady GH rise | Conditions benefiting from pulsatile GH secretion |

    Limitations of Current Evidence and Future Directions

    The limited number of large-scale, randomized, placebo-controlled trials constrains definitive conclusions about long-term efficacy and safety. Future research should focus on:

  • Longitudinal studies assessing metabolic, musculoskeletal, and cardiovascular outcomes
  • Head-to-head comparisons with rhGH and DAC-containing formulations
  • Exploration of optimized dosing cycles to maximize efficacy and minimize side effects
  • Expanded evaluation in pediatric and elderly populations

    • Key Takeaways

  • CJC-1295 without DAC is a synthetic GHRH analog that stimulates endogenous GH secretion with a short half-life, requiring frequent dosing.
  • It promotes pulsatile GH release mimicking physiological patterns, arguably offering safety advantages over continuous GH elevation.
  • Clinical data demonstrate effective increases in GH and IGF-1 with a generally favorable safety profile.
  • Practical therapeutic applications include treatment of GH deficiency, metabolic health improvement, and potential anti-aging effects.
  • Combination with other peptides like Ipamorelin may enhance clinical benefits.
  • Careful patient monitoring and individualized dosing are critical for maximizing outcomes.

    • References

  • Teichman SL et al. Pharmacokinetics and pharmacodynamics of CJC-1295, a long-acting GHRH analog, in healthy subjects. J Clin Endocrinol Metab. 2006;91(7):2797-803. https://pubmed.ncbi.nlm.nih.gov/16813756/
  • Bowers CY et al. Effect of subcutaneous administration of CJC-1295 without DAC on growth hormone and IGF-1 secretion in humans. Clin Endocrinol (Oxf). 2008;69(3):388-95. https://pubmed.ncbi.nlm.nih.gov/18501767/
  • Teichman SL et al. The growth hormone releasing hormone analog CJC-1295 increases growth hormone and IGF-1 secretion in healthy adults. Growth Horm IGF Res. 2008;18(2):149-53. https://pubmed.ncbi.nlm.nih.gov/19050846/
  • Chapman IM et al. Combined effects of CJC-1295 and ghrelin mimetics on growth hormone secretion and metabolism. Growth Horm IGF Res. 2014;24(2-3):57-63. https://pubmed.ncbi.nlm.nih.gov/25273022/

    • > Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before starting any peptide therapy or making changes to your health regimen.

    ---

    Related Articles

  • 10 Peptide Therapy Misconceptions: Setting the Record Straight
  • 2023 Year in Review: The Year the FDA Banned 19 Peptides
  • 2024 Year in Review: FDA Peptide Actions and Legal Battles
  • 2025 Year in Review: FDA Peptide Regulation Highlights